A Single-Institution, Open-Label, Single-Arm phase1/2 Study of Measles Vaccine as Consolidation in Patients With Measles Virus-Positive, Stage 3B/4 Non-Small Cell Lung Cancer
This is a single-institution, non-randomized phase 1/2 study in patients with
locally-advanced or metastatic NSCLC in remission after receiving standard systemic
chemotherapy of four cycles of combination chemotherapy consisting of four cycles of
cisplatin combined with vinorelbine.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess progression-free survival (PFS) and overall survival (OS) in patients with NSCLC in remission receiving subcutaneous live-attenuated measles virus vaccine as consolidation therapy in patients with measles-positive tumors.
Israel: Ministry of Health